Suivre
Abonner Astellas Pharma Europe Limited

Astellas Pharma Europe Limited

Filtre
  • 07.02.2011 – 14:21

    Astellas Enters into Partnership With Optimer on Life-Saving Antibiotic Fidaxomicin

    Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. announced today that it has entered into an exclusive collaboration and license agreement with Optimer Pharmaceuticals Inc., San Diego for the development and commercialisation of fidaxomicin, an investigational antibiotic for Clostridium difficile infection (CDI) in Europe and certain other countries ...

  • 17.01.2011 – 18:34

    Astellas Enters Into License Agreement With TOLMAR

    Tokyo (ots/PRNewswire) - Astellas Pharma Inc. announced today that its European subsidiary Astellas Pharma Europe Ltd.("Astellas Pharma Europe", headquarters: Stains, U.K.)" acquired the license for commercialization of the treatment for advanced prostate cancer Eligard(R) from TOLMAR Inc. ("TOLMAR", headquarters: Colorado, U.S.A.) on December 22, 2010 in a selection of Asian, Middle Eastern, North African and ...

  • 20.04.2010 – 07:03

    Urology and Transplantation Will Drive Future Growth as Astellas Begins Move into Oncology

    London, April 20, 2010 (ots/PRNewswire) - Today, on the fifth anniversary since its formation, Astellas Pharma Europe has confirmed that it will continue its emphasis on transplantation and urology while moving towards a new vision to build a strong presence in oncology. Astellas has shown robust growth since its creation, expanding its reach into new therapeutic ...

  • 01.12.2009 – 08:07

    Men, Partners and Patients in Europe United Against Prostate Cancer

    Barcelona, Spain (ots/PRNewswire) - - New Survey Highlights Need for Education Resources, Critical Role of Physician in Patient Communication and Importance of Maintaining Normal Lifestyle During Treatment Findings from a survey of European prostate cancer patients, presented at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC) in ...

  • 22.06.2009 – 13:08

    NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)

    San Mateo, California and Staines, England (ots/PRNewswire) - - Conference Call Today at 9:00am ET - Covers Europe, Middle East and Africa - Includes Licensing Option and Development Funding for NGX-1998 NeurogesX, Inc. (NASDAQ: NGSX) and Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo based Astellas Pharma Inc. announced ...

  • 07.05.2008 – 13:43

    Astellas' Mycamine(R) (micafungin) Licensed for Use in Europe to Treat Serious Fungal Infections

    Staines, England (ots/PRNewswire) - The European Medicines Agency (EMEA) has announced the marketing authorisation of Mycamine(R), Astellas Pharma Europe's treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Mycamine(R) will initially be available ...